While point of care (POC) antigen tests have a purpose in diagnosing COVID-19, they are difficult and resource intensive to scale to address high-volume testing needs. Beckman Coulter’s $4 SARS-CoV-2 antigen test makes large-scale, serial testing programs feasible and affordable. Feinglass, M.D., MPH, chief medical officer for Beckman Coulter. “We are offering our solution at $4 per test because it’s only with affordable and regular testing that we can address disparities and promote equity in COVID-19 testing, which is vital to address COVID-19-related health gaps and advance health equity among high-risk and underserved populations, including racial and ethnic minority groups and people living in rural areas,” said Shamiram R. Our antigen assay makes the regular testing part of this equation a reality by enabling institutions and communities to implement low-cost, frequent, mass COVID-19 testing with automation, ease of handling and speed to enable scalability.”īeckman Coulter’s antigen test can be used for testing in high-risk settings, such as nursing homes, hospitals, universities and other group settings where repeat testing, coupled with relevant clinical information, could identify those with a SARS-CoV-2 infection to minimize transmission. “The key to saving lives while vaccines are being put into arms is still masking, social distancing, regular testing, tracing and isolation. government’s goal to expand screening because this is the right way to open up our schools, our economy and get people back to work in tandem with the massive vaccination drive that is underway,” said Julie Sawyer Montgomery, president of Beckman Coulter Diagnostics. Results can be delivered in as little as 30 minutes on Beckman Coulter’s immunoassay analyzers, including the DxI 800 high-throughput analyzer that can process up to 200 samples every 60 minutes. government’s plan to invest more than $12 billion to expand COVID-19 testing with its high-throughput, high-quality lab antigen test, Access SARS-CoV-2 Ag, ideal for mass screening testing.īeckman Coulter announced in December that its $4 antigen test will be available to all customers and has a confirmed 93% positive predictive agreement (PPA) and 100% negative predictive agreement (NPA). Some photos may be stock photos to get an idea of what is being offered for sale.Īny weights and dimensions provided in the listing are estimates so therefore you should not rely on them for the most accurate shipping quotation.įor more information on this Beckman Coulter Access 2 or other used laboratory equipment please contact us at +1-85.Beckman Coulter, a clinical diagnostics leader, has announced its commitment to support the U.S. The photos provided are given to display the overall condition of the equipment and all items found in the photos may not be included in the sale. The written description provided for this equipment is what is being offered for sale.
#Dxi beckman coulter license
Typically any warranty, service contract or license for the equipment is not transferable but may be under certain circumstances and will be explicitly stated in the listing. It is encouraged that you inspect this equipment if possible. This Beckman Coulter Access 2 is being sold “as is, where is” unless otherwise noted. Onboard refrigerated storage of up to 24 assays.Unique, assay-specific protocols for optimal assay performance.Proven chemiluminescent and magnetic particle separation technology.
#Dxi beckman coulter pro
Remote monitoring and instrument diagnostics capability through PRO ServiceĮstablished performance for confidence in patient results.Reliable uptime with fewer emergency service calls Rapid kinetics for improved turnaround time.
Random access for running any combination of samples at any time.Loading capacity of 60 samples at one time.One of the smallest footprints in its class.Maximized productivity in a minimal footprint It is compact in size similar to a benchtop system.
The Beckman Coulter Access 2 Immunoassay Analyzer has the robustness of a reference lab Immunoassay Analyzer.